Latest Market Expansion News

Bioxyne Limited has upgraded its FY2025 revenue guidance to approximately $28 million, driven by strong domestic performance and significant progress in European and UK markets. The company also advances its psychedelic medicines pipeline, positioning itself for sustained growth.

Adveritas Limited has raised $8.5 million through an oversubscribed institutional placement, positioning itself for expansion into the US market and accelerated product development.

Sprintex Limited has boosted its Türkiye presence by extending its exclusive distribution deal, securing a new A$377,000 order, and launching larger Jet Blowers aimed at industrial and municipal markets.

Vita Life Sciences projects solid revenue growth of up to 16% for the first half of 2025, driven by strong performance in Australia, Malaysia, and Singapore, even as sales in China dip below last year’s levels.

4DMedical has renewed and expanded its contract with Stanford University’s 3DQ Lab to include its innovative CT – VQ™ imaging technology ahead of FDA clearance, marking a significant step in its U.S. market expansion.

Harvest Technology Group reports it is one year ahead of its 3-Year Pathway to Profit plan, forecasting a significant reduction in EBITDA loss for FY25 and unveiling plans for its AI-powered NEON platform launch in 1H26.

dorsaVi has secured exclusive worldwide rights to cutting-edge RRAM technology from NTU Singapore, promising to revolutionize its wearable sensor products with enhanced performance and energy efficiency. This strategic move positions the company for expansion into healthcare, elite sports, and industrial IoT markets.

Cettire Limited reports a slight 1.7% increase in sales revenue for the year-to-date FY25 amid ongoing global luxury market challenges, including US tariff impacts and volatile demand. The company focuses on emerging markets expansion and improving profitability despite margin pressures.

Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.

Telix Pharmaceuticals showcased its global theranostic radiopharmaceutical portfolio, highlighting FDA approvals, clinical progress, and a robust commercial expansion plan at its 2025 Investor Day.

FOS Capital has secured $3.7 million through a placement to fund its acquisition of Aldridge Traffic Systems, aiming to expand its footprint in the Australian lighting market. The deal includes key assets and intellectual property, positioning FOS for accelerated growth.

Optiscan Imaging Ltd has launched InSpecta™, a cutting-edge microscopic imaging device tailored for veterinary medicine, marking its strategic entry into a booming $12 billion US market. The device promises to revolutionize diagnostics and treatment for companion animals with real-time, non-invasive imaging.